Conversely, inhibitors of amino acid transporters, such as 2-amino-2-norbornanecarboxylic acid (BCH) and KYT0353 (JPH203), have shown efficacy in reducing tumour size by pharmacologically inhibiting of Jh-21 in RasV12scrib−/− malignant tumours through mTOR signalling downregulation [43]. The gene discussed is MTOR; the disease is neoplasm.